Overview

Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer

Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, non-randomized, Phase II study of patients with previously untreated NSCLC not amenable to radiotherapy or surgical treatment. The planned enrollment for this trial is 78 patients (including a 10% rate for inevaluable patients). There will be a total of 39 patients in each cohort (Cohorts A and B).
Phase:
Phase 2
Details
Lead Sponsor:
SCRI Development Innovations, LLC
Collaborators:
Bristol-Myers Squibb
Genentech, Inc.
Treatments:
Bevacizumab
Carboplatin
Epothilones